Clinical contribution of 18F-FDG PET/CT in patients with pediatric bone tissue and soft tissue sarcoma; A retrospective study Contribución clínica de la PET/TC con [18F]FDG en pacientes pediátricos con sarcoma de tejido óseo y de tejidos blandos: un estudio retrospectivo


ENGİN M. N., BURAL G. G., GÜLER E., BOZ A.

Revista Espanola de Medicina Nuclear e Imagen Molecular, 2026 (SCI-Expanded, Scopus) identifier

  • Yayın Türü: Makale / Tam Makale
  • Basım Tarihi: 2026
  • Doi Numarası: 10.1016/j.remn.2025.500252
  • Dergi Adı: Revista Espanola de Medicina Nuclear e Imagen Molecular
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, DIALNET
  • Anahtar Kelimeler: 18F-FDG, Child, Positron emission tomography, Prognosis, Sarcoma, Survival
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Objective To assess whether parameters derived from 18F-FDG PET/CT imaging could be used for prognostic evaluation in pediatric patients with bone and soft tissue sarcomas. Material and methods This retrospective study included pediatric patients diagnosed with sarcoma who underwent 18F-FDG PET/CT between February 2013 and January 2021. A total of 63 patients were evaluated. Anatomical tumor volume, standardized uptake values (SUV), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured. Progression-free survival (PFS) and overall survival (OS) were calculated. Cox regression analysis was performed to identify independent predictors. Results The mortality rate was 31.7%, and the median OS was 54.9 months. Lung ( P <.001) and lymph node metastases ( P =.049) were associated with shorter OS. Younger age at diagnosis ( P =.014), higher anatomical tumor volume ( P =.002), and lung metastasis ( P =.004) were independently associated with increased mortality risk. High MTV was independently associated with higher progression risk ( P <.001). Conclusion Anatomical tumor volume and lung metastasis predict mortality, while MTV predicts progression in pediatric sarcoma. Further prospective studies are needed to validate these findings.